ATE276744T1 - Neutrale-kationische lipide zur verabreichung von nukleinesäuren und arzneimitteln - Google Patents

Neutrale-kationische lipide zur verabreichung von nukleinesäuren und arzneimitteln

Info

Publication number
ATE276744T1
ATE276744T1 AT00970729T AT00970729T ATE276744T1 AT E276744 T1 ATE276744 T1 AT E276744T1 AT 00970729 T AT00970729 T AT 00970729T AT 00970729 T AT00970729 T AT 00970729T AT E276744 T1 ATE276744 T1 AT E276744T1
Authority
AT
Austria
Prior art keywords
neutral
administration
nucleic acids
cationic lipids
medicinal products
Prior art date
Application number
AT00970729T
Other languages
English (en)
Inventor
Shi Kun Huang
Samuel Zalipsky
Wei-Ming Zhang
Bei Jin
Yolanda P Quinn
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE276744T1 publication Critical patent/ATE276744T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00970729T 1999-10-08 2000-10-10 Neutrale-kationische lipide zur verabreichung von nukleinesäuren und arzneimitteln ATE276744T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15869399P 1999-10-08 1999-10-08
PCT/US2000/027974 WO2001026629A2 (en) 1999-10-08 2000-10-10 Neutral-cationic lipid for nucleic acid and drug delivery

Publications (1)

Publication Number Publication Date
ATE276744T1 true ATE276744T1 (de) 2004-10-15

Family

ID=22569279

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00970729T ATE276744T1 (de) 1999-10-08 2000-10-10 Neutrale-kationische lipide zur verabreichung von nukleinesäuren und arzneimitteln

Country Status (17)

Country Link
US (2) US6974589B1 (de)
EP (1) EP1223916B1 (de)
JP (1) JP2003511405A (de)
KR (1) KR100723852B1 (de)
CN (2) CN1378536A (de)
AT (1) ATE276744T1 (de)
AU (2) AU7868400A (de)
CA (1) CA2386164A1 (de)
DE (1) DE60014133T2 (de)
DK (1) DK1223916T3 (de)
ES (1) ES2226932T3 (de)
HU (1) HUP0203117A3 (de)
IL (1) IL148968A0 (de)
MX (1) MXPA02002899A (de)
NO (1) NO20021615D0 (de)
WO (2) WO2001026625A2 (de)
ZA (1) ZA200202726B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4558952B2 (ja) 1999-04-23 2010-10-06 アルザ コーポレイション リポソームにおいての使用のための開裂可能な結合を有する複合体
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
WO2001026625A2 (en) * 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
DE10207177A1 (de) 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
HUE036916T2 (hu) * 2004-05-05 2018-08-28 Silence Therapeutics Gmbh Lipidek, lipid komplexek és ezek alkalmazása
EP1935434A1 (de) * 2006-12-19 2008-06-25 Novosom AG Konstruktion und Verwendung von transfektionsverstärkenden Elementen
PT2147122E (pt) 2007-04-20 2014-10-15 Sigma Tau Rare Diseases S A Terapia enzimática antitumoral
CN101475503B (zh) * 2008-12-15 2012-02-15 山东大学 一种新型阳离子类脂及其制备方法和应用
EP2532649B1 (de) * 2011-06-07 2015-04-08 Incella GmbH Aminolipide, deren Synthese und Verwendungen davon
AU2012267531B2 (en) 2011-06-08 2017-06-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
PT2833869T (pt) * 2012-04-04 2020-11-25 Samyang Biopharmaceuticals Método de preparação de uma composição para administração de um fármaco aniónico
CN105585598B (zh) * 2014-10-20 2019-02-19 湖南师范大学 甘露糖衍生物阳离子脂质体纳米颗粒的制备方法
SG10202104058XA (en) * 2015-10-14 2021-05-28 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
CN107200841B (zh) * 2016-03-17 2019-02-01 华东师范大学 一种培化二酰甘油的合成方法
BR112019022016A2 (pt) * 2017-04-19 2020-05-12 Apa- Advanced Technologies Ltd. Lipossomas fusogênicos, composições, kits e uso dos mesmos no tratamento do câncer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5965434A (en) 1994-12-29 1999-10-12 Wolff; Jon A. Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO2000030444A1 (en) 1998-11-25 2000-06-02 Vanderbilt University Cationic liposomes for gene transfer
WO2001026625A2 (en) 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery

Also Published As

Publication number Publication date
AU778817B2 (en) 2004-12-23
US20050260261A1 (en) 2005-11-24
AU7868400A (en) 2001-04-23
WO2001026629A3 (en) 2002-05-10
NO20021615L (no) 2002-04-05
EP1223916A2 (de) 2002-07-24
ES2226932T3 (es) 2005-04-01
DK1223916T3 (da) 2005-01-31
CN1915968A (zh) 2007-02-21
HUP0203117A2 (hu) 2003-01-28
HUP0203117A3 (en) 2005-06-28
WO2001026629A2 (en) 2001-04-19
NO20021615D0 (no) 2002-04-05
US6974589B1 (en) 2005-12-13
WO2001026625A2 (en) 2001-04-19
KR20020063875A (ko) 2002-08-05
KR100723852B1 (ko) 2007-05-31
IL148968A0 (en) 2002-11-10
CA2386164A1 (en) 2001-04-19
DE60014133T2 (de) 2005-02-03
MXPA02002899A (es) 2002-10-23
AU8006400A (en) 2001-04-23
JP2003511405A (ja) 2003-03-25
CN1378536A (zh) 2002-11-06
ZA200202726B (en) 2003-06-25
EP1223916B1 (de) 2004-09-22
DE60014133D1 (de) 2004-10-28

Similar Documents

Publication Publication Date Title
DE60014133D1 (de) Neutrale-kationische lipide zur verabreichung von nukleinesäuren und arzneimitteln
HK1043796A1 (en) Novel phosphorus-containing prodrugs
ATE178067T1 (de) Camptothecinderivate
GR77296B (de)
WO2002007677A3 (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
ATE141048T1 (de) Verwendung von polyaminderivaten zur verstärkung der zellularen immunität
FR2681864B1 (fr) Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CY1106058T1 (el) Σταθερες συνθεσεις οξαπενεμ-3-καρβοξυλικων οξεων με συν-λυοφιλοποιηση με φαρμακευτικους φορεις
ATE43348T1 (de) Acylierte cytidin-diphosphat-choline, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
PE68299A1 (es) 1,2,3,4-tetrahidroisoquinolinas terapeuticas
MX9804752A (es) Conjugados covalentes de lipidos-acidos fosfonocarboxilicos, la produccion de los mismos asi como su uso como agentes farmaceuticos antivirales .
IT1276161B1 (it) Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
HK1049152B (zh) 1，4-脫氫吡啶-5-羧酸酯衍生物和其製備方法
SE9702173D0 (sv) Nya kolhydrater och deras användning
FR2777888B1 (fr) Nouveaux derives de l'acide (3,4,7,8,9,10-hexahydro-6,10- dioxo-6h-pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de medicaments
DE69533833D1 (de) Verfahren zur Herstellung von Indolopyrrolocarbazol-Derivaten
TW345579B (en) Cyanoethylmelamine derivatives and method for producing them
IT1248068B (it) Derivati dell'eseridina ad attivita' anticolinesterasi, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties